Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMTX NYSE:OGN NASDAQ:RARE NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$61.50+1.2%$59.79$1.16▼$14.10$2.66B-0.12189,291 shs235,643 shsOGNOrganon & Co.$10.60+0.2%$9.73$8.01▼$19.83$2.74B0.63.79 million shs2.87 million shsRAREUltragenyx Pharmaceutical$28.37-0.1%$29.00$25.81▼$57.99$2.73B0.211.32 million shs2,228 shsRZLTRezolute$8.74+2.6%$6.75$2.21▼$8.81$786.87M0.03954,788 shs5,339 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics+1.16%+2.66%+1.90%+11.81%+27.82%OGNOrganon & Co.-0.12%+2.08%+12.15%+5.65%-46.42%RAREUltragenyx Pharmaceutical-3.63%-3.66%-4.63%-24.13%-50.66%RZLTRezolute+4.67%+10.36%+21.71%+96.77%+77.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$61.50+1.2%$59.79$1.16▼$14.10$2.66B-0.12189,291 shs235,643 shsOGNOrganon & Co.$10.60+0.2%$9.73$8.01▼$19.83$2.74B0.63.79 million shs2.87 million shsRAREUltragenyx Pharmaceutical$28.37-0.1%$29.00$25.81▼$57.99$2.73B0.211.32 million shs2,228 shsRZLTRezolute$8.74+2.6%$6.75$2.21▼$8.81$786.87M0.03954,788 shs5,339 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics+1.16%+2.66%+1.90%+11.81%+27.82%OGNOrganon & Co.-0.12%+2.08%+12.15%+5.65%-46.42%RAREUltragenyx Pharmaceutical-3.63%-3.66%-4.63%-24.13%-50.66%RZLTRezolute+4.67%+10.36%+21.71%+96.77%+77.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMTXGemini Therapeutics 0.00N/AN/AN/AOGNOrganon & Co. 2.80Moderate Buy$17.3364.06% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$81.50186.97% UpsideRZLTRezolute 3.14Buy$14.5070.19% UpsideCurrent Analyst Ratings BreakdownLatest RZLT, OGN, RARE, and GMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/22/2025RZLTRezoluteGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.009/18/2025RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.009/18/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$12.009/18/2025RZLTRezoluteBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.009/9/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/5/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$105.009/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/8/2025RAREUltragenyx PharmaceuticalCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$136.00 ➝ $128.008/6/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$112.00 ➝ $105.007/28/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$80.007/14/2025RAREUltragenyx PharmaceuticalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$35.00 ➝ $34.00(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AOGNOrganon & Co.$6.40B0.43$4.91 per share2.15$1.83 per share5.77RAREUltragenyx Pharmaceutical$560.23M4.89N/AN/A$2.76 per share10.29RZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AOGNOrganon & Co.$864M$2.693.932.820.9611.15%163.88%6.99%10/30/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.53N/AN/AN/A-87.34%-237.48%-37.66%11/4/2025 (Estimated)RZLTRezolute-$74.41M-$0.97N/AN/AN/AN/A-65.03%-58.86%11/6/2025 (Estimated)Latest RZLT, OGN, RARE, and GMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/17/2025Q4 2025RZLTRezolute-$0.23-$0.26-$0.03-$0.26N/AN/A8/5/2025Q2 2025OGNOrganon & Co.$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27-$1.17+$0.10-$1.17$161.37 million$166.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMTXGemini TherapeuticsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.76%N/A2.97%N/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ALatest RZLT, OGN, RARE, and GMTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025OGNOrganon & Co.quarterly$0.020.9%8/15/20258/15/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMTXGemini TherapeuticsN/A71.4971.49OGNOrganon & Co.11.981.651.13RAREUltragenyx PharmaceuticalN/A2.452.30RZLTRezoluteN/A14.3714.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMTXGemini Therapeutics75.42%OGNOrganon & Co.77.43%RAREUltragenyx Pharmaceutical97.67%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipGMTXGemini Therapeutics12.90%OGNOrganon & Co.1.40%RAREUltragenyx Pharmaceutical5.50%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableOGNOrganon & Co.4,000259.97 million256.33 millionNot OptionableRAREUltragenyx Pharmaceutical1,29496.37 million91.07 millionOptionableRZLTRezolute4090.81 million74.11 millionOptionableRZLT, OGN, RARE, and GMTX HeadlinesRecent News About These CompaniesRezolute (NASDAQ:RZLT) Given "Buy" Rating at GuggenheimSeptember 24 at 2:48 AM | americanbankingnews.comQ3 Earnings Forecast for Rezolute Issued By WedbushSeptember 23 at 2:57 AM | americanbankingnews.comRezolute's (RZLT) "Buy" Rating Reiterated at GuggenheimSeptember 22 at 9:40 AM | marketbeat.comWhat is Wedbush's Forecast for Rezolute Q3 Earnings?September 22 at 2:30 AM | marketbeat.comHC Wainwright Estimates Rezolute's Q1 Earnings (NASDAQ:RZLT)September 22 at 2:29 AM | marketbeat.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - Time to Buy?September 20, 2025 | marketbeat.comHC Wainwright Weighs in on Rezolute FY2030 EarningsSeptember 20, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Receives "Outperform" Rating from WedbushSeptember 20, 2025 | americanbankingnews.comRezolute's (RZLT) Outperform Rating Reaffirmed at WedbushSeptember 19, 2025 | marketbeat.comRezolute price target raised to $20 from $15 at MaximSeptember 19, 2025 | msn.comBTIG Research Reiterates "Buy" Rating for Rezolute (NASDAQ:RZLT)September 19, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Earns "Buy" Rating from BTIG ResearchSeptember 19, 2025 | americanbankingnews.comRezolute (NASDAQ:RZLT) Posts Earnings Results, Misses Estimates By $0.04 EPSSeptember 18, 2025 | marketbeat.comRezolute, Inc.: Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 18, 2025 | finanznachrichten.deRezolute, Inc. Reports Fiscal 2025 Financial ResultsSeptember 17, 2025 | tipranks.comRezolute reports Q4 EPS (26c), consensus (23c)September 17, 2025 | msn.comRezolute, Inc. Reports Q4 and Full Year Fiscal 2025 Financial Results and Updates on Ersodetug Development ProgressSeptember 17, 2025 | quiverquant.comQRezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 17, 2025 | globenewswire.comRezolute Stock: FDA Fast Track Fuels 2025 Breakout...September 17, 2025 | marketbeat.comAcadian Asset Management LLC Grows Stake in Rezolute, Inc. $RZLTSeptember 17, 2025 | marketbeat.comRezolute: FDA Pivotal Trial Alignment Change Further Bolsters ErsodetugSeptember 16, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAmazon Faces Rare Downgrade—Is the Rally at Risk?By Sam Quirke | September 2, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025MP Materials: How One Move Redefined the U.S. Magnet Supply ChainBy Jeffrey Neal Johnson | August 27, 2025ACM Research: Why This Chinese Chip Stock Is Just Getting StartedBy Jeffrey Neal Johnson | September 1, 2025Rezolute Stock: FDA Fast Track Fuels 2025 BreakoutBy Thomas Hughes | September 17, 2025RZLT, OGN, RARE, and GMTX Company DescriptionsGemini Therapeutics NASDAQ:GMTX$61.50 +0.71 (+1.16%) As of 09/22/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Organon & Co. NYSE:OGN$10.60 +0.03 (+0.24%) As of 09:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Ultragenyx Pharmaceutical NASDAQ:RARE$28.37 -0.03 (-0.11%) As of 09:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Rezolute NASDAQ:RZLT$8.74 +0.22 (+2.61%) As of 09:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Mega-Cap Giants Just Increased Dividends by 7% or More 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
